Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."

TSX:VRX - Post Discussion

VALEANT PHARMACEUTICALS INTL INC > Valeant beats estimates
View:
Post by domcolumba on Aug 08, 2017 7:10am

Valeant beats estimates

https://ca.finance.yahoo.com/news/valeant-announces-second-quarter-2017-110000442.html

Might be a good day.
GoooooooooooooooooooooooooooooooooooooooooooooooooooooooooooooValeant

Looks like Joe Pappa is DELIVERING
Comment by domcolumba on Aug 08, 2017 7:36am
John Zeckner on BNN Joe Pappa is turning the company around. Valeant up 6% pre-market.
Comment by domcolumba on Aug 08, 2017 7:51am
Revenue declined to $2.233 million from $2.42 million, above the FactSet consensus of $2.228 million. 
Comment by domcolumba on Aug 08, 2017 7:54am
Excluding items, the Laval, Quebec-based company earned $1.05 per share, ahead of the average analyst estimate of 94 cents, according to Thomson Reuters I/B/E/S.
Comment by FerrariPalmbeac on Aug 08, 2017 9:22am
Well , I said $1.03 ! so much for the other analysts.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities